Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

A phase II clinical trial with single-agent decitabine was conducted in older patients (≥60 years) with previously untreated acute myeloid leukemia (AML) who were not candidates for or who refused intensive chemotherapy. Subjects received low-dose decitabine at 20 mg/m(2) i.v. over 1 h on days 1 to...

Full description

Saved in:
Bibliographic Details
Main Authors: Blum, William, Garzon, Ramiro, Klisovic, Rebecca B., Schwind, Sebastian, Walker, Alison, Geyer, Susan, Liu, Shujun, Havelange, Violaine, Becker, Heiko, Schaaf, Larry, Mickle, Jon, Devine, Hollie, Kefauver, Cheryl, Devine, Steven M., Chan, Kenneth K., Heerema, Nyla A., Bloomfield, Clara D., Grever, Michael R., Byrd, John C., Villalona-Calero, Miguel, Croce, Carlo M., Marcucci, Guido
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2010
Subjects:
Biological Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2867720/
https://ncbi.nlm.nih.gov/pubmed/20368434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1002650107
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items